Icothera (Icodextrin, Magnesium Chloride Hexahydrate, Sodium Chloride, Calcium Chloride Dihydrate, Sodium Lact)

Icodextrin is a high‑molecular‑weight polymer that remains in the peritoneal cavity after infusion. It generates an osmotic gradient across the peritoneal membrane, drawing water and small solutes from the bloodstream into the dialysate, thereby achieving continuous ultrafiltration without relying on glucose metabolism.

The prescribed dose of Icothera is determined by the treating nephrologist based on the patient’s dialysis regimen, body size, and fluid removal goals. Dosing is individualized and should follow the clinician’s instructions and the product’s prescribing information.

Safety data for icodextrin in pregnancy or lactation are limited. The product’s pregnancy category is not established, and it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Icothera, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Unlike glucose‑based solutions, icodextrin provides a prolonged osmotic effect with less rapid absorption, allowing longer dwell times and more consistent ultrafiltration. It also reduces the risk of hyperglycemia and glucose‑related peritoneal membrane changes, making it advantageous for patients who require extended exchanges.

Icothera should be stored at controlled room temperature, typically below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and freezing. Once opened, use according to the manufacturer’s aseptic guidelines and discard any unused portion after the recommended time.

Icothera is administered by intraperitoneal infusion using a sterile catheter. The solution is introduced into the peritoneal cavity, where it remains for a prescribed dwell period before being drained. Administration follows the dialysis protocol set by the treating clinician, whether for continuous ambulatory or automated exchanges.

The most serious risks include severe allergic reactions such as anaphylaxis, peritonitis indicated by cloudy effluent and abdominal pain, metabolic acidosis, and significant electrolyte disturbances. Patients should be monitored closely for signs of infection, hypersensitivity, and fluid overload during therapy.

Icothera should be avoided in individuals with known hypersensitivity to icodextrin or any component of the formulation. It is also contraindicated in patients with active peritonitis, uncontrolled infections, or those who cannot tolerate intraperitoneal solutions. Clinical judgment is required for patients with severe hepatic impairment.